About: http://webisa.webdatacommons.org/51088142

Property	Value
http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://www.w3.org/ns/prov#Entity
http://www.w3.org/ns/prov#value	The biologic DMARDs abatacept (Orencia) and rituximab (Rituxan) should be reserved for patients with at least moderate disease activity and poor disease prognosis who were not helped by methotrexate and other nonbiologic DMARDs.
http://www.w3.org/ns/prov#wasQuotedFrom	carolinashealthcare.org